降脂药与β受体阻滞剂对卵巢癌生存的影响:不列颠哥伦比亚人群队列研究
该研究基于加拿大不列颠哥伦比亚1997至2015年确诊的上皮性卵巢癌患者行政数据,纳入4207人,采用时依性变量分析他汀或β受体阻滞剂使用与生存的关联。结果显示诊断后任何他汀使用与更好的卵巢癌生存相关(aHR=0.76,95%CI 0.64-0.89),主要由诊断后新起始使用驱动(aHR=0.67,95%CI 0.51-0.89);β受体阻滞剂使用与生存无统计学显著关联。
要点
- 诊断后他汀使用与卵巢癌生存改善相关(aHR=0.76,95%CI 0.64-0.89)。
- 该关联主要由诊断后新起始他汀使用驱动(aHR=0.67,95%CI 0.51-0.89)。
- β受体阻滞剂使用与卵巢癌生存无统计学显著关联。
核心结论
- 诊断后他汀使用与卵巢癌患者生存改善相关,β受体阻滞剂使用与生存无显著关联。
- 鉴于文献中该发现的一致性,建议开展他汀用于卵巢癌患者的随机临床试验。
研究设计与样本
- 基于人群的队列研究,链接加拿大不列颠哥伦比亚1997至2015年确诊的上皮性卵巢癌患者行政数据,共纳入4207人。
- 使用时依性变量定义他汀或β受体阻滞剂的任何使用、累积使用时长及按诊断前后起始的分组,采用Cox比例风险模型估计与生存的关联。
主要发现
- 全队列中诊断后任何他汀使用与更好的卵巢癌生存相关(aHR=0.76,95%CI 0.64-0.89)。
- 浆液性癌患者中诊断后他汀使用与更好的生存相关(aHR=0.80,95%CI 0.67-0.96)。
- 诊断后新起始他汀使用与更好的生存相关(aHR=0.67,95%CI 0.51-0.89)。
- 诊断前已使用并继续他汀者呈现生存改善趋势(aHR=0.83,95%CI 0.68-1.00)。
- β受体阻滞剂使用与生存无统计学显著关联。
临床怎么用
- 对于上皮性卵巢癌患者,诊断后使用他汀可能与生存改善相关,但当前证据尚不足以常规推荐用于延长生存。
- β受体阻滞剂的使用不应以改善卵巢癌生存为目的进行处方。
- 可考虑与患者讨论他汀使用的潜在获益与不确定性,并鼓励参与相关随机临床试验。
局限性
- 研究为观察性设计,可能存在未测量混杂。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Research examining survival among people with ovarian cancer following use of statins or β-blockers has been conflicting. Many studies to date have suffered from immortal time bias and/or had limited power. To address these limitations, we used time-dependent analyses to study the association between statin or β-blocker use among all people diagnosed with an epithelial ovarian cancer in British Columbia, Canada between 1997 and 2015. METHODS: Population-based administrative data were linked for 4207 people with ovarian cancer. Statin or β-blocker use was examined using time-dependent variables for any use, cumulative duration of use and by user-group according to whether use was initiated before or after their ovarian cancer diagnosis. Cox proportional hazards models were run to estimate the association between statin or β-blocker use and survival. RESULTS: Any postdiagnosis use of statins was associated with better ovarian cancer survival in the full cohort (adjusted hazard ratio (aHR) = 0.76, 95% CI 0.64, 0.89) and among women with serous cancers (aHR = 0.80, 95%CI 0.67-0.96). This was primarily driven by new use post-diagnosis (aHR = 0.67, 95%CI, 0.51-0.89), but there was a trend towards better survival among those who continued use from before diagnosis (aHR 0.83, 95%CI, 0.68-1.00). There was no statistically significant association between β-blocker use and survival. CONCLUSION: Postdiagnosis statin use was associated with improved survival among people with ovarian cancer. Given the consistency of this finding in the literature, we recommend a randomized clinical trial of statin use in people with ovarian cancer.
引用
- Hanley GE, Kaur P, Berchuck A, et al. Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada. Gynecol Oncol. 2021. PMID: 34090707. doi:10.1016/j.ygyno.2021.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。